Loading...
SELLAS Life Sciences Group, Inc.
SLS•NASDAQ
Healthcare
Biotechnology
$2.17
$0.005(0.23%)
SELLAS Life Sciences Group, Inc. (SLS) Financial Performance & Statements
Review SELLAS Life Sciences Group, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
16.78%
↑ 16.78%
Net Income Growth
17.30%
↑ 17.30%
Operating Cash Flow Growth
-12.71%
↓ 12.71%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-193.67%
↓ 193.67%
ROIC
-99.51%
↓ 99.51%
SELLAS Life Sciences Group, Inc. (SLS) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for SELLAS Life Sciences Group, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | |
| R&D Expenses | $4.44M | $4.36M | $5.19M | $5.11M |
| SG&A Expenses | $2.48M | $2.97M | $2.44M | $4.53M |
| Operating Expenses | $6.92M | $7.33M | $7.62M | $9.64M |
| Total Costs & Expenses | $6.92M | $7.33M | $7.62M | $9.64M |
| Interest Income | $181000.00 | $221000.00 | $151000.00 | $79000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $0.00 | $9.64M |
| EBITDA | -$6.92M | -$7.33M | -$7.62M | $0.00 |
| EBITDA Ratio | ||||
| Operating Income | -$6.92M | -$7.33M | -$7.62M | -$9.64M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $181000.00 | $221000.00 | $151000.00 | $79000.00 |
| Income Before Tax | -$6.74M | -$7.11M | -$7.47M | -$9.57M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$9.64M |
| Net Income | -$6.74M | -$7.11M | -$7.47M | -$9.57M |
| Net Income Ratio | ||||
| EPS | -$0.01 | -$0.01 | -$0.01 | -$0.02 |
| Diluted EPS | -$0.01 | -$0.01 | -$0.01 | -$0.02 |
| Weighted Avg Shares Outstanding | $73.98M | $614.29M | $518.67M | $403.32M |
| Weighted Avg Shares Outstanding (Diluted) | $73.98M | $614.29M | $518.67M | $403.32M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan